Impact of efalizumab on psoriasis-specific patient-reported outcomes: results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis

Journal of Drugs in Dermatology,  Jan-Feb, 2004  by Alan Menter,  Mark Kosinski,  Brian W. Bresnahan,  Kim A. Papp,  John E. Ware

• E-mail
• Print
• Link

References

1. Vensel E, Hilley T, Trent J, et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol 2000; 43:858-860.

2. Psoriasis Questions and Answers. Available at: http://www.psoriasis.org/facts/faq. Accessed: November 30, 2003.

3. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132:236-244.

4. Koo J. Population-based epidemiological study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14:485-496.

5. McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997; 36:388-394.

6. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280-284.

7. Gupta MA, Gupta AK, Haberman HF. Psoriasis and psychiatry. Gen Hosp Psychiatry 1987; 157-166.

8. Ramsay B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988; 118:195-210.

9. Fried RG, Friedman S, Paradis C. Trivial or terrible? The psychosocial impact of psoriasis. Int J Dermatol 1995; 34:101-105.

10. Wahl A. The impact of psoriasis on psychosocial life domains: A review. Scand J Caring Sci 1997; 11:243-249.

11. Jowett S, Ryan T. Skin disease and handicap: An analysis of the impact of skin conditions. Soc Sci Med 1985; 20:425-429.

12. O'Neil P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis. Br Med J 1996; 313:919-921.

13. Feldman SR, Fleischer AB, Jr., Reboussin DM, et al. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37:564-569.

14. Leary MR, Rapp SR, Herbst KC, et al. Interpersonal concerns and psychological difficulties of psoriasis patients: Effects of disease severity and fear of negative evaluation. Health Psychol 1998; 17:530-536.

15. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability and other major medical diseases. J Am Acad Dermatol 1999; 41:410-417.

16. National Psoriasis Foundation 2003.

17. Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: A comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999; 140:672-676.

18. Finlay AY. Quality of life measurement in dermatology: A practical guide. Br J Dermatol 1997; 136:305-314.

19. Finlay AY, Kelly SE. Psoriasis: An index of disability. Clin Exp Dermatol 1987; 12:8-11.

20. Gottlieb AB. Psoriasis. Dis Manag Clin Outcomes 1998; 1:195-202.

21. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332:581-588.

22. Fortune DG, Main CJ, O'Sullivan TM, et al. Quality of life in patients with psoriasis: The contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997; 137:755-760.

23. Root S, Kent G, Al-Abadie MSK. The relationship between severity, disability and psychological distress in patients undergoing PUVA treatment for psoriasis. Dermatology 1994; 189:234-237.